JP2022518598A5 - - Google Patents

Info

Publication number
JP2022518598A5
JP2022518598A5 JP2021544519A JP2021544519A JP2022518598A5 JP 2022518598 A5 JP2022518598 A5 JP 2022518598A5 JP 2021544519 A JP2021544519 A JP 2021544519A JP 2021544519 A JP2021544519 A JP 2021544519A JP 2022518598 A5 JP2022518598 A5 JP 2022518598A5
Authority
JP
Japan
Prior art keywords
bonds
formula
group
amino acid
hydrophilic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021544519A
Other languages
English (en)
Japanese (ja)
Other versions
JP7421232B2 (ja
JP2022518598A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2020/052159 external-priority patent/WO2020157128A1/en
Publication of JP2022518598A publication Critical patent/JP2022518598A/ja
Publication of JP2022518598A5 publication Critical patent/JP2022518598A5/ja
Application granted granted Critical
Publication of JP7421232B2 publication Critical patent/JP7421232B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021544519A 2019-01-30 2020-01-29 フッ化ケイ素アクセプタ置換放射性医薬品とその前駆体 Active JP7421232B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19154636 2019-01-30
EP19154636.5 2019-01-30
PCT/EP2020/052159 WO2020157128A1 (en) 2019-01-30 2020-01-29 Silicon-fluoride acceptor substituted radiopharmaceuticals and precursors thereof

Publications (3)

Publication Number Publication Date
JP2022518598A JP2022518598A (ja) 2022-03-15
JP2022518598A5 true JP2022518598A5 (cg-RX-API-DMAC7.html) 2022-12-23
JP7421232B2 JP7421232B2 (ja) 2024-01-24

Family

ID=65268875

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021544519A Active JP7421232B2 (ja) 2019-01-30 2020-01-29 フッ化ケイ素アクセプタ置換放射性医薬品とその前駆体

Country Status (7)

Country Link
US (1) US12576169B2 (cg-RX-API-DMAC7.html)
EP (1) EP3917581A1 (cg-RX-API-DMAC7.html)
JP (1) JP7421232B2 (cg-RX-API-DMAC7.html)
CN (1) CN113677375B (cg-RX-API-DMAC7.html)
AU (1) AU2020213892B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021012110A2 (cg-RX-API-DMAC7.html)
WO (1) WO2020157128A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202005282D0 (en) 2020-04-09 2020-05-27 Blue Earth Diagnostics Ltd Pharmaceutical Formulations
EP4185336A1 (en) * 2020-07-23 2023-05-31 Technische Universität München Silicon-containing ligand compounds
JP2024544153A (ja) * 2021-11-16 2024-11-28 テクニシェ ユニバーシタット ミュンヘン 溶解した[18f]フッ化物を含む組成物の調製方法およびその方法によって得ることができる組成物
GB202207372D0 (en) 2022-05-19 2022-07-06 Blue Earth Diagnostics Ltd Synthesis of fluorosilyl compounds

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070072831A1 (en) 2005-05-16 2007-03-29 Gilead Sciences, Inc. Integrase inhibitor compounds
DK2187965T3 (da) 2007-08-17 2020-01-20 Purdue Research Foundation Psma-bindingsligand-linker-konjugater og fremgangsmåder til anvendelse
EP3209336B1 (en) * 2014-10-20 2019-12-11 Deutsches Krebsforschungszentrum 18f-tagged inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
EP3303349B1 (en) 2015-05-26 2022-07-06 The Regents of the University of California Novel heteroaromatic silicon-fluoride-acceptors useful for 18f labeling of molecules and biomolecules, and methods of preparing same
KR20240027896A (ko) 2017-07-28 2024-03-04 테크니쉐 우니베르지테트 뮌헨 이중 모드 방사성 트레이서 및 치료법

Similar Documents

Publication Publication Date Title
JP2954354B2 (ja) 造影用のテクネチウム‐99m標識ペプチド
KR0156541B1 (ko) 펩티드 유도체
JPWO2020145228A5 (cg-RX-API-DMAC7.html)
CA2819850C (en) Psma-targeted dendrimers
RU2010140846A (ru) Конъюгаты антагониста пептида аналога бомбезина
JP4171484B2 (ja) ペプチド−キレート化剤複合体
JPH0421671B2 (cg-RX-API-DMAC7.html)
KR100330794B1 (ko) 혈관질병진단제
AU2020257786B2 (en) Novel radiolabelled compounds for diagnosis or treatment of prostate-specific membrane antigen-expressing cancer
CA1340556C (en) High molecular compound comprising unit of asialoglyco-protein acceptor-directing compound and unit of chelate-forming compound chemically bonded thereto, and its utilization
KR20130132935A (ko) Nota에 의해 복합체를 형성한 알루미늄―〔18〕플루오라이드로 표지된 her2 결합 펩티드
JP6164556B2 (ja) 非特異的腎集積が低減された放射性標識ポリペプチド作製用薬剤
KR20130132939A (ko) 18f - 함유 유기실리콘 화합물로 표지된 her2 결합 펩티드
JP2020512348A5 (cg-RX-API-DMAC7.html)
JP2025507971A (ja) 前立腺特異的膜抗原を標的とする放射性標識化合物
CN116981486A (zh) 双模式放射性示踪剂和治疗剂
AU2020213892B2 (en) Silicon-fluoride acceptor substituted radiopharmaceuticals and precursors thereof
AU2022320317A1 (en) Radiolabeled compound and use thereof
JP2001114792A (ja) ビスホスホン酸誘導体およびその放射性核種標識体
CN115484992B (zh) 药物制剂
FI104409B (fi) Kelaatinmuodostajia ja niitä sisältäviä, diagnostiikassa käytettäviä komplekseja
US6458337B1 (en) Diagnostic imaging contrast agent with improved in serum relaxivity
JP2025532619A5 (cg-RX-API-DMAC7.html)
US20240091390A1 (en) Improved cholecystokinin-2 receptor (cck2r) targeting for diagnosis and therapy
RU2021125318A (ru) Радиофармацевтические препараты, замещенные фторидом кремния, и их предшественники